评论文章
预后价值的KRAS基因突变结直肠的腹膜转移腺癌患者的生存
|
|
WT-KRAS (n= 74) |
MT-KRAS (n= 75) |
价值 |
|
| 性 |
| 男人(n= 85) |
43 (50.6%) |
42 (49.4%) |
0.46 |
| 女性(n= 64) |
31 (48.4%) |
33 (51.6%) |
|
| 年龄 |
| < 50 (n= 17) |
9 (53%) |
8 (47%) |
0.62 |
| 50 - 69 (n= 80) |
42 (52.5%) |
38 (47.5%) |
| > 69 (n= 52) |
23 (44.2%) |
29 (55.8%) |
|
| 位置 |
| 右结肠(n= 64) |
28 (43.7%) |
36 (56.3%) |
0.32 |
| 左结肠(n= 64) |
33 (51.5%) |
31 (48.5%) |
| 直肠(n= 21) |
13 (61.9%) |
8 (38.1%) |
|
| ECOG指数 |
| 0 (n= 34) |
20 (58.8%) |
14 (41.2%) |
0.15 |
| 1 - 2 (n= 115) |
54 (46.9%) |
61例(53.1%) |
|
| T台 |
| T3 (n= 68) |
33 (48.5%) |
35 (51.5%) |
0.46 |
| T4 (n= 81) |
41 (50.6%) |
40 (49.4%) |
|
| N阶段 |
| N0 (n= 27) |
18 (66.6%) |
9 (33.4%) |
0.04 |
| N1-2 (n= 122) |
56 (45.9%) |
66例(54.1%) |
|
| 诊断时间 |
| 同步(n= 77) |
36 (46.7%) |
41 (53.3%) |
0.28 |
| Metachronic (n= 72) |
38 (52.8%) |
34 (47.2%) |
|
| 网站的转移 |
| 腹膜(n= 61) |
36 (59%) |
25 (41%) |
0.08 |
| 腹膜+肝(n= 51) |
26 (51%) |
25 (49%) |
| 腹膜+肺(n= 8) |
3 (37.5%) |
5 (62.5%) |
| 多个(n= 29) |
9 (31%) |
20 (69%) |
|
| 等级分化 |
| 到中度(n= 111) |
61例(55%) |
50 (45%) |
0.02 |
| 可怜的(n= 38) |
13 (34.2%) |
25 (65.8%) |
|
| 组织学类型 |
| 典型的腺癌(n= 105) |
61例(58%) |
43 (42%) |
< 0.001 |
| 粘液性(n= 44) |
12 ((27.7%) |
32 (73.8%) |
|
| 腹膜癌指数 |
| 1 - 10 (n= 46) |
23 (50%) |
23 (50%) |
0.15 |
| 11日至20日(n= 63) |
36 (57.1%) |
27 (42.9%) |
| > 20 (n= 40) |
15 (37.5%) |
25 (62.5%) |
|
| 原发性肿瘤切除术 |
| 是的(n= 130) |
69例(53%) |
61例(47%) |
0.02 |
| 没有(n= 19) |
5 (26.3%) |
14 (73.7%) |
|
| 化疗治疗 |
| 5-FU-based程序加贝伐单抗、西妥昔单抗(n= 103) |
57 (55%) |
46 (45%) |
0.51 |
| 5-FU-based程序(n= 46) |
17 (37%) |
29 (63%) |
|
| HIPEC |
| 没有(n= 113) |
50 (44.2%) |
63例(55.8%) |
0.01 |
| 是的(n= 36) |
24 (66.6%) |
12 (33.4%) |
|
|
|
|
